Gibson Dunn Advised Nextech Ventures and EQT Life Sciences in $183 Million Series C Financing for Electra Therapeutics
Firm News | October 23, 2025
Gibson Dunn advised Nextech Ventures and EQT Life Sciences as co-lead investors in a $183 million Series C financing for Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer.
Our corporate team was led by partners Ryan Murr and Branden Berns and included associates Mark Goldman and Hannah Gonzalez.